XR Securities’s Ionis Pharmaceuticals IONS Stock Holding History

XR Securities’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,327	Closed	-$439K	–	273
2019 Q3	$439K	Buy	+7,327	New	+$478K	0.06%	69

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

XR Securities's IONS Position: Q4 2019 in Review

XR Securities sold out of Ionis Pharmaceuticals (IONS) in Q4 2019, closing a stake of 7,327 shares — an estimated $439K sold.

XR Securities first reported a position in IONS in Q3 2019 and held it in 1 quarter. The position peaked at $439K in Q3 2019. 390 funds tracked by Wall St. Rank hold IONS as of Q4 2019.

XR Securities reported no remaining Ionis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
XR Securities sold 7,327 Ionis Pharmaceuticals shares in Q4 2019, an estimated $439K.
XR Securities first reported a position in Ionis Pharmaceuticals in Q3 2019 and held it in 1 quarter.
XR Securities's Ionis Pharmaceuticals position peaked at $439K in Q3 2019.
390 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2019.

Based on XR Securities's 13F filing for Q4 2019, filed 6 Jan 2020.